Diagnosis and treatment of multiple sclerosis

British Medical Journal

Volumn 332, Issue 7540, 2006, Pages 525-527

  Murray, T J ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BACLOFEN; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; OXYBUTYNIN; PREDNISONE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE DISEASE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LEUKEMIA; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; CLASSIFICATION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE;

DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PROGNOSIS; RECURRENCE;

EID: 33644891895     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7540.525     Document Type: Review

References (18)

1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on die diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
2. Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, et al. Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. Acta Neurol Scand 2004;109:385-9.
3. Pittock SJ, McClelland RL, Mayr WT, Jorgensen NW, Weinshenker BG, Noseworthy J, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56:303-6.
4. Jacobs LD, Beck RW, Simon JH, Murray TJ, et al. Intramuscular interferon beta la therapy initiated during a first demyelinating event in multiple sclerosis. Champs study group. N Engl J Med 2000;343:898-904.
5. Murray TJ. Multiple sclerosis: the history of a disease. New York: Demos, 2005.
6. Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004;63:1079-80.
7. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 2002;58;169-78.
8. Giovannoni G, Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005;65:6-8.
9. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hoblfeld R, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65:40-7.
10. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized, multicenter trial. Lancet 2002;360:2018-25.
11. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for die treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332-8.
12. In: Cohen BA, Jeffery DR, eds. Identification of suboptimal responders to immune modulating agents and the role of mitoxantrone in worsening multiple sclerosis. Supplement to Neurology 2004;(suppl 6)63(12). [Nine articles.]
13. Novantrone prescribing information [package insert]. Serono. Available at www.novantrone.com.
14. Shapiro RT, Managing the symptoms of multiple sclerosis. 4th ed. New York: Demos, 2003.
15. Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry 2004;49:157-63.
16. Bowling AC. Alternative medicine and multiple sclerosis. New York: Demos, 2001.
17. Murray TJ. Complementary and alternative medicine for MS. Int MS J 2005;13:3.
18. Frohman EM, Goodin DS, Calabrese PA, CorboyJR, Coyle PK, Filippi M, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602-11.